Head-to-head · WeighScore
Boston Medical Group vs Ravia Health
The verdict
Boston Medical Group takes it — 61.9/100 to 59.2/100.
Boston Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Boston Medical Group is an established medical group running a 12-week compounded GLP-1 weight-loss programme.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Boston Medical Group | Ravia Health |
|---|---|---|
| WeighScore | 61.9/100 | 59.2/100 |
| Grade | C | C |
| Scorecard rank | #279 | #347 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | 7 states | 1 state |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #347 · C
Strengths
- Integrative psychiatry model combines GLP-1 weight-loss with mental health and metabolic care under one board-certified NP provider
- Founded by Dr. Raashida Portier (DNP, PMHNP-BC, FNP-BC); named clinician with dual board certifications in psychiatry and family medicine
- Membership-supported ongoing care from $49/month provides medication management structure with consistent follow-up
- Labs and metabolic workup available as part of integrative psychiatry model; lab testing noted in weight-loss program
- Weight-loss page claims nationwide availability via Lyv Health partnership for eligible patients
Where it loses points
- GLP-1 medication pricing fully gated — not disclosed until consultation; compounded vs. brand status unclear on public pages
- Primarily a psychiatric practice — weight loss is a secondary service, not the core offering or brand identity
- Core services explicitly Florida-only; nationwide weight-loss claim relies on Lyv Health partnership with unverified state coverage
- No LegitScript certification or third-party accreditation found on public pages
- Small single-provider practice with no published outcomes data or external reviews available
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.